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Career thoughts and recollections: 50 years publishing in The Journal of General Virology 1 
I was both delighted and honoured to receive a letter recently informing me that I had been elected as an 2 
honorary member of the Microbiology Society. I have been a member of the society (which I still refer to as 3 
SGM from force of habit) since 1972, and the Microbiology Society has had an important influence on me 4 
during most of my research career; I owe it a lot. I was surprised to learn in that letter that I had co-5 
authored 50 papers in the Journal of General Virology between 1969 and 2015. In fact, when I checked, the 6 
actual number is 51 and this encouraged me to look back and reflect on the immense changes that have 7 
occurred in my work personally and in the field of virology generally during the 50 years since my first JGV 8 
paper.  9 
I cut my teeth virologically in 1964 when I took up my first post ŝŶ&ƌĞĚƌŽǁŶ ?ƐůĂďŽƌĂƚŽƌǇĂƚthe Animal 10 
Virus Research Institute (now the Pirbright Institute) following my post-graduate studies at the University 11 
of Southampton. Fred was both my boss and mentor for many years after I joined his group and it was at 12 
Pirbright that I was exposed to the weird, wonderful and sometimes frightening world of foot-and-mouth 13 
disease. A passion for research into its causative agent, foot-and-mouth disease virus (FMDV), that was 14 
ĞŶŐĞŶĚĞƌĞĚǁŚŝůĞǁŽƌŬŝŶŐŝŶ&ƌĞĚ ?ƐŐƌŽƵƉ has remained with me ever since and I am still actively involved 15 
to this day.  16 
As in all spheres of scientific endeavour, the advances made over the past 50 years (the course of a single 17 
lifetime career in my case) have been amazing. These occurred through both small incremental steps and 18 
in quantum leaps, the latter often being driven by major technological developments. It is almost 19 
embarrassing now to look back at the impoverished level of understanding we had when I published my 20 
first JGV paper in 19691. Virus purification techniques, involving mostly ultracentrifugation procedures had 21 
been established by then but we had little idea of the antigenic structure and protein composition of the 22 
virus and determination of the nucleotide sequence of the viral genome was a far off dream. Serological 23 
experiments in those days involved the complement fixation test  ? has anybody heard of that now? In the 24 
early 70s major developments were made in techniques for protein separation and analysis. The era of SDS 25 
polyacrylamide gel electrophoresis had arrived and enabled us to demonstrate for the first time that the 26 
FMDV particle comprised multiple proteins2. I can remember bets being taken at scientific meetings during 27 
that period as to how many SDS PAGE profiles each speaker would present.  28 
Much of our work in the 70s was devoted to applying biophysical techniques to compare and contrast the 29 
properties of viruses within the picornavirus family in order to establish groupings for classification 30 
purposes. Methods such as nucleic acid base composition and buoyant density determination were used to 31 
define four groupings within the picornaviruses3  ? compare this with the latest score of 47 picornavirus 32 
genera4 resulting from increased virus isolations combined with genetic sequencing and bioinformatics. 33 
Methods to study virus replication and protein processing were heavily reliant on radiochemical labelling, 34 
often involving pulse-chase approaches. These methods enabled the unravelling of the complexities of 35 
processing of the picornavirus polyprotein and mapping of the genetic structure of the genome despite the 36 
lack of sequence information5.  37 
The 80s saw the introduction of three technical developments which had huge influences on virology 38 
generally and my personal interests in particular. The first of these, monoclonal antibodies, facilitated 39 
mapping of antigenic features of viruses such as FMDV. The second was molecular cloning and sequencing, 40 
which enabled the determination and manipulation of viral genomes. Finally, advances in X-ray 41 
crystallography meant that the structure of virions, such as picornaviruses, could be resolved in near 42 
atomic detail. A combination of these methods enabled us to identify a distinctive feature on the surface of 43 
the FMDV particle, the VP1 G-H loop, which was the target of a high proportion of the neutralising 44 
antibodies present in anti-FMDV sera. This information enabled us, in collaboration with ZŝĐŚĂƌĚ>ĞƌŶĞƌ ?Ɛ45 
group at the Scripps Institute, to explore the (then) incredibly exciting possibility of producing chemically 46 
synthesised vaccines. Indeed, we showed for the first time that small laboratory animals could be 47 
protected from challenge with virulent FMDV by immunisation with synthetic peptides representing the 48 
VP1 G-H loop sequence6. The crystal structure of the virus, dĞƚĞƌŵŝŶĞĚǁŝƚŚĂǀĞ^ƚƵĂƌƚ ?s group in Oxford, 49 
showed why peptide vaccines for FMDV were more successful than with other systems as the major 50 
epitope appears as a mobile loop on the virion surface, much like a synthetic peptide7, 8 (Fig. 1). Although 51 
practical synthetic vaccines against FMD were not realised, for a variety of reasons, their investigation 52 
opened up a number of important aspects of immunology and vaccine development. In attempting to 53 
optimise the immune response to purely synthetic immunogens, we were able to demonstrate the 54 
importance of Th cell epitopes9 ? immunological concepts that were in their infancy then.  We were also 55 
able to demonstrate the immunogenic potential of presenting antigenic epitopes in the context of 56 
particulate carriers (nanoparticles in modern parlance) by fusing peptide epitopes to the self-assembling 57 
hepatitis B core protein10. 58 
Cloning and sequencing of the FMDV genome was, and is, of huge importance for progressing our 59 
understanding of how the virus works. The FMDV genome was found to have a number of unusual/unique 60 
features that we are still trying to understand to this day. For example, a seventh of the genome comprises 61 
ƚŚĞƵŶƚƌĂŶƐůĂƚĞĚ ? ?ĞŶĚ ?ǁŚŝĐŚĐŽŶƚĂŝŶƐĂƚůĞĂƐƚ ?ĚŝƐƚŝŶĐƚĚŽŵĂŝŶƐ ?ĂŶĚƚŚĞƌĞĂƌĞ ?ĐŽƉŝĞƐŽĨƚŚĞZE62 
primer protein, VPg11, 12, 13. We still do not understand the roles of several of these unusual features, and 63 
the desire to resolve some of these intriguing problems is why I cannot give up yet.  64 
A new departure for me in the 90s was hepatitis C virus (HCV). Although the existence and importance of 65 
this cryptic human pathogen had been suspected for many years it was not finally identified until 1989 by 66 
DŝĐŚĂĞů,ŽƵŐŚƚŽŶ ?ƐŐƌŽƵƉ14. This was a triumph of the new molecular approaches to virus identification 67 
when the agent could not be grown using conventional culture techniques. The full significance of the virus 68 
for human health only became apparent following its formal identification and the development of 69 
diagnostic tests. The realisation that HCV infection usually leads to persistent infection with serious 70 
consequences in later life meant that it was an ideal target for antiviral intervention and the race was on to 71 
develop chemotherapeutic agents. I, together with a significant proportion of the virology community, 72 
joined the fray to discover vulnerable features of HCV replication which were suitable for therapeutic 73 
intervention. While with the Wellcome Foundation in the early 90s we worked on NS3, the viral protease15 74 
and following my move to the University of Leeds in 1996 and teaming up with Mark Harris, we extended 75 
our interests to include the hepatitis C virus non-structural proteins and the putative viroporin, P716, 17, 18.   76 
More recently, I have returned to practical work on FMDV. This was finally made possible when the 77 
regulatory authorities agreed that replicons are not viruses and pose no threat through accidental release 78 
of important pathogens to the environment. In collaboration with my colleague Nicola (Nic) Stonehouse 79 
here in Leeds we are capitalising on this decision and have an active programme of work addressing some 80 
of the unanswered questions (e.g. the functions of RNA elements within the UTRs, the complexities of 81 
polyprotein processing and the structure and functioning of replication complexes) about this remarkable 82 
virus that I alluded to at the start of these reminiscences. 83 
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Figure 1  In the image (based on the coordinates for the FMDV O1M receptor complex (PDB: 5NET), both the 92 
O1M virus and integrin receptor are depicted using a surface representation i.e the surface that would be 93 
traced out by the surface of the waters in contact with the protein at all possible positions (Connolly Surface). 94 
The capsid proteins are coloured with VP1 in blue, VP2 green and VP3 salmon and for the integrin, the alpha 95 
subunit is green and the beta subunit, red. The VP1 GH loop is drawn using semi-transparent magenta spheres 96 
(corresponding to the van der Waals radii of the atoms) in the 'up' orientation to engage with 97 
receptor.  Courtesy of E. Fry and D. Stuart. 98 
Reproduced from: Rowlands D. J.,  Foot-and-mouth disease viruses. Encyclopedia of Virology, Third 99 
Edition (2008), vol. 2, pp. 265-274 100 
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